HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune attacks are key issues for cell transplantation. To assess the safety and the immune reactions after iPS cells-derived retinal pigment epithelium (iPS-RPE) transplantation, we transplanted HLA homozygote iPS-RPE cells established at an iPS bank in HLA-matched patients with exudative age-related macular degeneration. In addition, local steroids without immunosuppressive medications were administered. We monitored immune rejections by routine ocular examinations as well as by lymphocytes-graft cells immune reaction (LGIR) tests using graft RPE and the patient’s blood cells. In all five of the cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by clumps or an area of increased pigmentation at 6 months, which became stable with no further abnormal growth in the graft during the 1-year observation period. Adverse events observed included corneal erosion, epiretinal membrane, retinal edema due to epiretinal membrane, elevated intraocular pressure, endophthalmitis, and mild immune rejection in the eye. In the one case exhibiting positive LGIR tests along with a slight fluid recurrence, we administrated local steroid therapy that subsequently resolved the suspected immune attacks. Although the cell delivery strategy must be further optimized, the present results suggest that it is possible to achieve stable survival and safety of iPS-RPE cell transplantation for a year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This was further confirmed in a clinical trial study with five recruited HLA-matched patients who received HLA-matched RPE cells [97]. In all five cases, survival of transplanted cells was observed one year later, without the need for systemic immune suppression.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061 · cited 8×
“Therefore, the present clinical study was designed to use allografts of iPS-RPE cells from an HLA homozygous donor prepared at the Center for iPS Cell Research and Application (CiRA) iPS bank [21] for wet AMD patients with the same HLA haplotype identity.”
BackgroundMethodInfluentialSelf-citationPrevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509 · cited 4×
“The marker and function for the iPS cells-derived RPE cells were similar to that observed with our previous RPE cells [20].”
BackgroundMethodResultInfluentialSelf-citationImmunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444 · cited 1×
“Moreover, we have as of yet no definitive answer as to how the immune rejection in the eye occurred in only one case, even though several events such as iPS-associated immune attacks [32], minor antigens, natural killer cell attacks (e.”
BackgroundEmbryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409 · cited 1×
“However, it was also found that some of these patients had adverse events due to systemic immunosuppressive medications [28], which can be a physical burden in elderly patients.”
BackgroundSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“However, anti-VEGF treatments often require continual injections for years and thus, it can be difficult to retain visual acuity in real-world clinics [8].”
BackgroundThe Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807 · cited 2×
“Moreover, the eye is also known to be a unique organ with a unique environment that has both anti-inflammatory and immunosuppressive mechanisms [16,17].”
Background
Cited by
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
Yamanaka, S. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.014 · Cited by 1,213
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2024.12.005 · Cited by 196
Yoshida, S., Kato, T. M., Sato, Y., Umekage, M., Ichisaka, T., Tsukahara, M., Takasu, N., & Yamanaka, S. (2023) · Med · doi:10.1016/j.medj.2022.10.003 · Cited by 134
Hirami, Y., Mandai, M., Sugita, S., Maeda, A., Maeda, T., Yamamoto, M., Uyama, H., Yokota, S., Fujihara, M., Igeta, M., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.004 · Cited by 138
Self-citationJarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabidès, M., Domingues, S., Chose, O., Habeler, W., Lorant, J., et al. (2021) · Cells · doi:10.3390/cells10020240 · Cited by 116
“A clinical trial in Japan used one HLA-matched hiPSC-RPE cell line to treat five wet-AMD patients [125].”
MethodImmunological aspects of RPE cell transplantation
Sugita, S., Mandai, M., Kamao, H., & Takahashi, M. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100950 · Cited by 77
Self-citationUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“This was further confirmed in a clinical trial study with five recruited HLA-matched patients who received HLA-matched RPE cells [97].”
ResultLiu, Z., Parikh, B. H., Tan, Q. S. W., Wong, D. S. L., Ong, K. H., Yu, W., Seah, I. Y. J., Holder, G. E., Hunziker, W., Tan, G. S. W., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.007 · Cited by 67
“Future clinical trials involving hRPESC-RPE could include HLAmatching, as used in recent iPSC-RPE allogeneic transplantation with HLA-matched, major histocompatibility complex-homozygous RPE, and might possibly remove the need for systemic immunosuppression (Sugita et al., 2020).”
MethodA novel glaucoma approach: Stem cell regeneration of the trabecular meshwork
Coulon, S. J., Schuman, J. S., Du, Y., Fard, M. R. B., Ethier, C. R., & Stamer, W. D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101063 · Cited by 66
Strategies of pluripotent stem cell-based therapy for retinal degeneration: update and challenges
Maeda, T., Mandai, M., Sugita, S., Kime, C., & Takahashi, M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.001 · Cited by 74
Self-citationLuce, E., Messina, A., Duclos‐Vallée, J., & Dubart‐Kupperschmitt, A. (2021) · Hepatology · doi:10.1002/hep.31705 · Cited by 53
Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity
Flahou, C., Morishima, T., Takizawa, H., & Sugimoto, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662360 · Cited by 56
“April 2021 | Volume 12 AMD, age-related macular degeneration; GVHD, graft versus host disease; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; ARDS, acute respiratory distress syndrome; CMs, cardiomyocytes; MSCs, mesenchymal stromal cells; RPE, Retinal Pigment Epithelium.”
BackgroundInfluentialUyama, H., Mandai, M., & Takahashi, M. (2020) · Development Growth & Differentiation · doi:10.1111/dgd.12704 · Cited by 55
“…transplantation, subretinal pigmentation or an RPE layer-like reflex was observed by fundus photography and optical coherence tomography, indicating the integration of transplanted RPE cells (Liu et al., 2018; Mehat et al., 2018; Schwartz et al., 2015; Song et al., 2015; Sung et al., 2020).”
BackgroundSelf-citationTrends of Stem Cell Therapies in Age-Related Macular Degeneration
Maeda, T., Sugita, S., Kurimoto, Y., & Takahashi, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081785 · Cited by 55
“This study aimed to investigate the safety of six-loci HLA-matched allogeneic cell transplantation under local steroids only in order to standardize future cell therapies with iPS cell-derived RPE [9].”
BackgroundSelf-citationKagita, A., Lung, M. S. Y., Xu, H., Kita, Y., Sasakawa, N., Iguchi, T., Ono, M., Wang, X. H., Gee, P., & Hotta, A. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.013 · Cited by 50
“ssODN-Mediated One-Step Biallelic Modification to Convert HLA-C1 to HLA-C2 To facilitate HLA matching for allogeneic transplantation of iPSC derivatives, the use ofHLAhomozygous iPSC stocks has been investigated (Sugita et al., 2020).”
MethodCoco, R. M., Pastor‐Idoate, S., & Jimeno, J. C. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060865 · Cited by 56
“However, it resulted in an insufficient number of cells being delivered to the targeted area, which is another problem that should be addressed [111].”
BackgroundHypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E., et al. (2024) · Stem cell research & therapeutics · doi:10.1186/s13287-024-03810-4 · Cited by 40
“…have been proposed to overcome the hurdle, including transplantation of HLA-matched allogeneic induced pluripotent stem cells (iPSC)-derived cells [1], transplantation of allogeneic cells with the administration of an immunosuppressant [2–5], and development of genetically engineered…”
BackgroundGenetically engineered hypoimmunogenic cell therapy
Hotta, A., Schrepfer, S., & Nagy, A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00219-9 · Cited by 48
“Therapies derived from HLA-homozygous iPSCs are currently being used to treat patients with age-related macular degeneration 42 , ischaemic cardiomyopathy (NCT04696328, NCT04945018) 43 , retinitis pigmentosa 44 , Parkinson disease 45 , subacute spinal cord injury 46 , knee joint cartilage injury…”
Low Immunogenicity and Immunosuppressive Properties of Human ESC- and iPSC-Derived Retinas
Yamasaki, S., Sugita, S., Horiuchi, M., Masuda, T., Fujii, S., Makabe, K., Kawasaki, A., Hayashi, T., Kuwahara, A., Kishino, A., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.021 · Cited by 43
Self-citationLin, Y., Sato, N., Hong, S., Nakamura, K., Ferrante, E. A., Yu, Z., Chen, M. Y., Nakamura, D. S., Yang, X., Clevenger, R. R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.05.005 · Cited by 45
Clinical translation of human iPSC technologies: advances, safety concerns, and future directions
Dhaiban, S., Chandran, S., Noshi, M., & Sajini, A. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1627149 · Cited by 62
Hinkle, J. W., Mahmoudzadeh, R., & Kuriyan, A. E. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02546-9 · Cited by 47
Stem cell therapy in retinal diseases
Voisin, A., Pénaguin, A., Gaillard, A., & Leveziel, N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.361537 · Cited by 42
“In this context, RIKEN grafted five patients with HLA-matched allogenic hiPSC-RPE cells in 2017 (Sugita et al., 2020).”
MethodSarkar, A., Junnuthula, V., & Dyawanapelly, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910594 · Cited by 40
Pluripotent Stem Cells in Clinical Setting—New Developments and Overview of Current Status
Ilić, D., & Ogilvie, C. M. (2022) · Stem Cells · doi:10.1093/stmcls/sxac040 · Cited by 42
“US, China, Japan, and the UK are the only countries conducting both hESC- and hiPSC-based trials.”
BackgroundInfluentialMarkert, E. K., Klein, H., Viollet, C., Rust, W., Strobel, B., Kauschke, S. G., Makovoz, B., Neubauer, H., Bakker, R. A., & Blenkinsop, T. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.910040 · Cited by 40
“Another group used HLA-matched allogeneic-induced pluripotent stem cell–derived RPE transplanted into patients, and reported epiretinal membrane production as adverse events in two out of five individuals (Sugita et al., 2020).”
BackgroundNew trends in cellular therapy
Okano, H., & Sipp, D. (2020) · Development · doi:10.1242/dev.192567 · Cited by 39
“sufficiently controlled to access the efficacy of this therapeutic approach, and further optimization of the surgical procedure for the human iPSC-RPE cells transplantation will be necessary in future studies (Sugita et al., 2020).”
BackgroundGarcía-Delgado, A. B., Valdés-Sánchez, L., Morillo-Sánchez, M. J., Ponte, B., Diaz-Corrales, F. J. J., & de la Cerda, B. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01843-z · Cited by 40
“Years of preclinical studies have provided a firm base in which some small clinical trials have shown safety [85, 86].”
BackgroundStem Cell-based Treatment Strategies for Degenerative Diseases of the Retina
Nair, D. S. R., & Thomas, B. B. (2021) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666210804112104 · Cited by 38
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 38
Self-citationRecent Progress in Retinal Pigment Epithelium Cell-Based Therapy for Retinal Disease
Klymenko, V., Martinez, O. G. G., & Zarbin, M. A. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae004 · Cited by 47
“32,95 Nonetheless, the production of ESC and iPSC products is time and cost intensive (compare for example Sugita et al 24 and Mandai et al 20 ).”
BackgroundResultWatanabe, T., Shu, S. L., Río-Espínola, A. D., Ferreira, J. R., Bando, K., Lemmens, M., Pande, P., de Wolf, C., Chen, C. L., Ericson, E., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.04.062 · Cited by 36
Nishida, M., Tanaka, Y., Tanaka, Y., Amaya, S., Tanaka, N., Uyama, H., Masuda, T., Onishi, A., Sho, J., Yokota, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00703-x · Cited by 36
Self-citationLong-Term Transplant Effects of iPSC-RPE Monolayer in Immunodeficient RCS Rats
Nair, D. S. R., Zhu, D., Sharma, R., Camarillo, J. C. M., Bharti, K., Hinton, D., Humayun, M., & Thomas, B. (2021) · Cells · doi:10.3390/cells10112951 · Cited by 28
“RPE cells grafted as a suspension into the patient’s subretinal space survived in all five cases for more than one year [19].”
BackgroundInfluentialCompetency of iPSC-derived retinas in MHC-mismatched transplantation in non-human primates
Uyama, H., Tu, H., Sugita, S., Yamasaki, S., Kurimoto, Y., Matsuyama, T., Shiina, T., Watanabe, T., Takahashi, M., & Mandai, M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.09.014 · Cited by 30
“LGIR has already been used in our clinical study of hiPSC-RPE transplantation for neovascular age-related macular degeneration (AMD), which sensitively detected immune rejection associated with a very early clinical manifestation (Sugita et al., 2020).”
Self-citationCurrent Landscape of iPSC Haplobanks
Escribá, R., Beksaç, M., Griscelli, A. B., Glover, J. C., Koskela, S., Latsoudis, H., Querol, S., & Álvarez-Palomo, B. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10783-7 · Cited by 30
Sakai, D., Mandai, M., Hirami, Y., Yamamoto, M., Shinichiro, I. T. O., Igarashi, S., Yokota, S., Uyama, H., Fujihara, M., Maeda, A., et al. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100770 · Cited by 29
“9,11 The RPE sheet transplantation closely approximates physiological conditions and potentially enhances graft function.”
Self-citationInduced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Gaykema, L. H., van Nieuwland, R. Y., Lievers, E., Moerkerk, W. B. J., de Klerk, J. A., Dumas, S. J., Kers, J., Zaldumbide, A., van den Berg, C. W., & Rabelink, T. J. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad069 · Cited by 29
“Successful transplantations have been performed with iPSC-derived cells for patients with age-related macular degeneration, 8,9 and Parkinson’s disease.”
Clinical translation of pluripotent stem cell-based therapies: successes and challenges
Christiansen, J. R., & Kirkeby, A. (2024) · Development · doi:10.1242/dev.202067 · Cited by 29
Cell reprogramming: methods, mechanisms and applications
Zhu, F., & Nie, G. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00229-x · Cited by 27
“…al. 2022; Liuyang et al. 2023); the circumvention of immune responses via the utilization of autologous iPSC-derived cell products (Mandai et al. 2017; Sharma et al. 2019; Wang et al. 2024c) or HLA-matched iPSC-derived cell products (Sugita et al. 2016, 2020; Kawamura et al. 2016; Xu et al. 2019).”
Current status and future directions of clinical applications using iPS cells—focus on Japan
Tsujimoto, H., & Osafune, K. (2021) · FEBS Journal · doi:10.1111/febs.16162 · Cited by 30
Raimondi, R., Zollet, P., Rosa, F. P. D., Tsoutsanis, P., Stravalaci, M., Paulis, M., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020682 · Cited by 26
“, with the purpose of minimizing immune reactions, developed a cellular suspension of hiPS-derived RPE cells obtained from HLA-homozygous haplotypes matching those of patients with exudative AMD [26].”
BackgroundMethodLee, Y. J., & Jo, D. H. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10802-7 · Cited by 27
“For example, a clinical trial has been conducted involving the use of RPE cells derived from HLA-matched allogeneic iPSCs for macular degeneration [ 190 ].”
Zhu, X., Chen, Z., Wang, L., Ou, Q., Feng, Z., Xiao, H., Shen, Q., Li, Y., Jin, C., Xu, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05199-5 · Cited by 25
A ROCK Inhibitor Promotes Graft Survival during Transplantation of iPS-Cell-Derived Retinal Cells
Ishida, M., Sugita, S., Makabe, K., Fujii, S., Futatsugi, Y., Kamao, H., Yamasaki, S., Sakai, N., Maeda, A., Mandai, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063237 · Cited by 24
“Details of the LGIR assay (Ki-67 FACS analysis), including antibody information, are described in a previous report [26,31].”
MethodSelf-citationiPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 24
Sugita, S., Futatsugi, Y., Ishida, M., Edo, A., & Takahashi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186507 · Cited by 23
“In fact, we recently reported that one retinal patient had immune rejection of HLA-matched iPS-RPE cell transplantation [8] TLT-2 (TREML2) is a type I transmembrane protein in the TREM family.”
BackgroundSelf-citationKashani, A. H. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000838 · Cited by 22
Progress of iPS cell-based transplantation therapy for retinal diseases
Akiba, R., Takahashi, M., Baba, T., & Mandai, M. (2023) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00974-5 · Cited by 22
“report 5 cases of allogenic iPS cells’ derived RPE cell transplantation to neovascular AMD patients, and the results showed that the allogenic iPS-RPE can survive in a host retina without use of systemic immunosuppressive medications [21].”
MethodResultSelf-citationCell maturation influences the ability of hESC-RPE to tolerate cellular stress
Viheriälä, T., Hongisto, H., Sorvari, J., Skottman, H., Nymark, S., & Ilmarinen, T. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02712-7 · Cited by 21
Dujardin, C., Habeler, W., Monville, C., Letourneur, D., & Simón‐Yarza, T. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.003 · Cited by 27
Exploring Stem-Cell-Based Therapies for Retinal Regeneration
Radu, M., Brănişteanu, D. C., Pîrvulescu, R. A., Dumitrescu, O.-M., Ionescu, M. A., & Zemba, M. (2024) · Life · doi:10.3390/life14060668 · Cited by 22
“In a distinct clinical trial, conducted by Sugita et al. [59] (UMIN 000026003), five patients diagnosed with neovascular age-related macular degeneration were enrolled.”
BackgroundSubmacular integration of hESC-RPE monolayer xenografts in a surgical non-human primate model
Liu, Z., Ilmarinen, T., Tan, G. S. W., Hongisto, H., Wong, E. Y. M., Tsai, A. S. H., Al-Nawaiseh, S., Holder, G. E., Su, X., Barathi, V. A., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02395-6 · Cited by 20
Replacement of the Trabecular Meshwork Cells—A Way Ahead in IOP Control?
Fan, X., Bilir, E. K., Kingston, O. A., Oldershaw, R. A., Kearns, V., Willoughby, C. E., & Sheridan, C. (2021) · Biomolecules · doi:10.3390/biom11091371 · Cited by 20
“Studies involving the transplantation of iPSC-TM are still in their infancy compared to elsewhere in the eye [85].”
BackgroundGene and cell therapy for age-related macular degeneration: A review
Trincão-Marques, J., Ayton, L. N., Hickey, D. G., Marques‐Neves, C., Guymer, R. H., Edwards, T. L., & Sousa, D. C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.002 · Cited by 26
Sakai, D., Takagi, S. T., Totani, K., Yamamoto, M., Matsuzaki, M., Yamanari, M., Sugiyama, S., Yokota, S., Maeda, A., Hirami, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11192-x · Cited by 19
Self-citationRao, R. C., Arduini, B. L., Borden, S., Sareen, D., Svendsen, C. N., Lee, P. P., Ryan, C. J., Kodati, S., Nyaiburi, C., Wolsieffer, K., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.08.012 · Cited by 19
Choi, S. W., Seo, S., Hong, H. K., Yoon, S. J., Kim, M., Moon, S., Lee, J. Y., Lim, J., Lee, J. B., & Woo, S. J. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-023-00555-8 · Cited by 18
“Similarly, subretinal transplantation of a suspension or sheet of induced pluripotent stem cell (iPSC)-derived RPEs resulted in stable surgical outcomes in patients with AMD [14, 15].”
BackgroundGraft survival of major histocompatibility complex deficient stem cell-derived retinal cells
Ishida, M., Masuda, T., Sakai, N., Nakai-Futatsugi, Y., Kamao, H., Shiina, T., Takahashi, M., & Sugita, S. (2024) · Communications Medicine · doi:10.1038/s43856-024-00617-5 · Cited by 15
“The LGIR test was developed as an in vitro assay for the evaluation of immune rejection and for the selection of ef fi cacious medications 22,24,32 , whichhasbeenusedinourclinicaltrials 1,12 .”
BackgroundMethodSelf-citationEdo, A., Sugita, S., Futatsugi, Y., Sho, J., Onishi, A., Kiuchi, Y., & Takahashi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217831 · Cited by 18
“We also reported that immune rejection occurs in one of five age-related macular degeneration patients after allogeneic transplantation of iPSC-RPEs [10].”
BackgroundSelf-citationYamagishi, H., & Shigematsu, K. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0080 · Cited by 20
“They are moving forward with a clinical study in which allogeneic iPS cells generated from human cells with a type of HLA that is less prone to immune rejection are transformed into RPE cells, and a suspension containing the cells is transplanted into the patient’s eye (13), ((18)).”
BackgroundYang, Y., Hsiao, Y., Chang, K.-J., Foustine, S., Ko, Y., Tsai, Y.-C., Tai, H., Ko, Y., Chiou, S., Lin, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213794 · Cited by 18
“HLA-matched allogeneic transplantations can eliminate the need for immune suppression and are safer for the patients [60,61].”
100 plus years of stem cell research—20 years of ISSCR
Lendahl, U. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.04.004 · Cited by 18
“, 2017) and was later followed by an alternative strategy with banked HLA-matched allogeneic iPSCs to reduce the need of immunosuppression (Sugita et al., 2020).”
MethodPirsadeghi, A., Namakkoobi, N., Behzadi, M. S., Pourzinolabedin, H., Askari, F., Shahabinejad, E., Ghorbani, S., Asadi, F., Hosseini‐Chegeni, A., Yousefi‐Ahmadipour, A., et al. (2024) · Cells and Development · doi:10.1016/j.cdev.2024.203904 · Cited by 19
Reprogramming iPSCs to study age-related diseases: Models, therapeutics, and clinical trials
Esteves, F., Brito, D. V. C., Rajado, A. T., Silva, N., Apolónio, J. D., Roberto, V. P., Araújo, I. M., Nóbrega, C., Castelo‐Branco, P., Bragança, J., et al. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111854 · Cited by 18
Chang, Y., Velmurugan, B. K., Wen, Y., Huang, C., Tsai, R., & Ding, D. (2022) · Cell Transplantation · doi:10.1177/09636897221085901 · Cited by 16
iPSC-RPE in Retinal Degeneration: Recent Advancements and Future PerspectivesPreprint
Maeda, T., & Takahashi, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041308 · Cited by 17
Self-citationNew Prospects for Retinal Pigment Epithelium Transplantation
Gullapalli, V. K., & Zarbin, M. A. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000521 · Cited by 16
Burri, C., Al-Nawaiseh, S., Wakili, P., Salzmann, S., Krötz, C., Považay, B., Meier, C., Frenz, M., Szurman, P., Schulz, A., et al. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.10.17 · Cited by 14
“9,10 Although there are already promising results regarding RPE stem cell therapy in AMD, a methodology with minimum impact on surrounding tissues for the desirable removal of the diseased host RPE cells preceding the recolonization is still missing.”
Clinical Trials of Stem Cell Therapy in Japan: The Decade of Progress under the National Program
Enosawa, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237030 · Cited by 14
“2022, 11, 7030. https://doi.org/10.3390/ jcm11237030 Academic Editors: Hirofumi Noguchi and Takashi Kenmochi Received: 25 October 2022 Accepted: 25 November 2022 Published: 28 November 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- iations.”
BackgroundInfluentialRobotic cell processing facility for clinical research of retinal cell therapy
Terada, M., Kogawa, Y., Shibata, Y., Kitagawa, M., Kato, S., Iida, T., Yorimitsu, T., Kato, A., Matsukuma, K., Maeda, T., et al. (2023) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2023.10.004 · Cited by 14
Self-citationThree-Dimensional Bioprinting for Retinal Tissue Engineering
Wu, K. Y., Osman, R. M., Kearn, N., & Kalevar, A. (2024) · Biomimetics · doi:10.3390/biomimetics9120733 · Cited by 14
Morizane, A., Yamasaki, E., Shindo, T., Anazawa, T., Sawamoto, N., Shima, A., Yamakado, H., Nakanishi, E., Sawamura, M., Taruno, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.012 · Cited by 16
Kajita, K., Nishida, M., Kurimoto, Y., Yokota, S., Sugita, S., Semba, T., Shirae, S., Hayashi, N., Ozaki, A., Miura, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60895-w · Cited by 13
Self-citationHarnessing Global HLA Data for Enhanced Patient Matching in iPSC Haplobanks
Maiers, M. J., Sullivan, S. K., McClain, C., Leonhard‐Melief, C., Turner, M. L., & Turner, D. M. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.11.001 · Cited by 13
Retina stem cells, hopes and obstacles
German, O. L., Vallese-Maurizi, H., Soto, T. B., Rotstein, N. P., & Politi, L. E. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i10.1446 · Cited by 13
Status and prospects for the development of regenerative therapies for corneal and ocular diseases
Takayanagi, H., & Hayashi, R. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.09.001 · Cited by 12
“Since then, the transplantation of allogeneic iPSC-derived RPE cell suspensions and retinal organoids containing photoreceptor cells have progressed to clinical application [55,56].”
BackgroundhPSC-based treatment of retinal diseases – Current progress and challenges
Ozaki, A., Sakai, D., & Mandai, M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115587 · Cited by 12
Self-citationBiological aging clocks in health and disease
Wyss‐Coray, T., & Topol, E. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04495-3 · Cited by 16
Designed peptide-grafted hydrogels for human pluripotent stem cell culture and differentiation
Wang, T., Liu, Q., Chang, Y., Liu, J., Yu, T., Maitiruze, K., Ban, L.-K., Sung, T., Kumar, S. S., Renuka, R. R., et al. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb02521c · Cited by 12
Towards Stem/Progenitor Cell-Based Therapies for Retinal Degeneration
Liu, H., Lu, S., Chen, M., Gao, N., Yang, Y., Hu, H., Ren, Q., Liu, X., Chen, H., Zhu, Q., et al. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10740-4 · Cited by 12
“HLA typing is used to match patients and donors for transplantation, making iPSCs a promising approach to avoid immune rejection [ 68, 69].”
Morizane, A., & Takahashi, J. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-212608 · Cited by 8
Morita, Y., Kishino, Y., Fukuda, K., & Tohyama, S. (2022) · Cell Proliferation · doi:10.1111/cpr.13248 · Cited by 14
“HLA homozygote hPSC-RPE cells have already been applied to five HLA-matched patients, and all five of the cases were stable with no abnormal graft growth during the 1-year observation period.(110) In addition to the treatment of agerelated macular degeneration, clinical trials in retinitis pigmentosa,”
MethodBiomaterials used for tissue engineering of barrier-forming cell monolayers in the eye
Sasseville, S., Karami, S., Tchatchouang, A., Charpentier, P., Anney, P., Gobert, D., & Proulx, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1269385 · Cited by 11
“In another clinical trial, allogeneic iPS-RPE cells of an HLA homozygous donor were transplanted to 5 HLA-matched patients with wet AMD (Sugita et al., 2020).”
Selective nanosecond laser removal of retinal pigment epithelium for cell therapy
Nguyen, V. P., Karoukis, A. J., Hu, J., Wei, Z., Yang, D., Fahim, A. T., Wang, X., & Paulus, Y. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-69917-z · Cited by 11
“Stem cell therapy (SCT) and regenerative medicine are demonstrating significant promise to improve treatment outcomes for various diseases, including diabetic retinopathy 1–3 , degenerative retinopathies including retinitis pigmentosa 4,5 , and geographic atrophy (GA) from dry age-related macular degeneration (AMD) 6–…”
BackgroundInfluentialBellingrath, J.-S., Li, K. V., Aziz, K., Izzi, J. M., Liu, Y., & Singh, M. S. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2024.1377098 · Cited by 12
Pluripotent stem cell-based cell therapies: Current applications and future prospects
Wang, G., Heimendinger, P., Ramelmeier, R. A., & Wang, W. (2022) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2022.100390 · Cited by 11
Hall, J. C., Paull, D. J., Pébay, A., & Lidgerwood, G. E. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14128 · Cited by 12
“Unfortunately to date this therapy shows meagre outcomes with minimal improvement in retinal sensitivity but no statistically significant increase in visual acuity or patient reported quality of life.(44,45,94,96) HALL ET AL.”
BackgroundChen, Q., Zhang, T., Chen, Z., Zeng, J., O’Connor, A., Zhu, M., Gillies, M. C., Lu, F., & Zhu, L. (2025) · Biomolecules · doi:10.3390/biom15081167 · Cited by 10
Cell therapy for retinal disease
Yalla, G. R., & Kuriyan, A. E. (2024) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001034 · Cited by 10
“Rather than utilizing hESC-RPE, a study used HLA-matched iPSC-RPE cells which were injected in the subretinal space following PPV in five NV-AMD patients refractory to anti-VEGF injections (UMIN000026003) [16 ].”
BackgroundMethodMakabe, K., Sugita, S., Futatsugi, Y., & Takahashi, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073396 · Cited by 10
“Moreover, after transplantation of retinal pigment epithelial cell allografts in patients with age-related macular degeneration, an increase in CD11b-positive cells (monocytes/macrophages) in the blood was shown; one patient suffered from immune rejection [50].”
BackgroundSelf-citationHarary, P. M., Jgamadze, D., Kim, J., Wolf, J. A., Song, H., Ming, G., Cullen, D. K., & Chen, H.-C. I. (2023) · Brain Sciences · doi:10.3390/brainsci13121654 · Cited by 11
“In addition, autologous iPSCs have been used to generate patient-matched grafts, which enable transplantation strategies that dispense with the need for immunosuppression [17].”
MethodPioneering stem-cell trials in Japan report promising early results
Mallapaty, S. (2022) · Nature · doi:10.1038/d41586-022-02232-7 · Cited by 10
Brýmová, A., Rodríguez-Jiménez, F. J., Konrad, A., Nemesh, Y., Thottappali, M. A., Artero‐Castro, A., Nyshchuk, R., Kolesnikova, A. F., Müller, B., Studenovská, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202412301 · Cited by 9
Ito, A., Ye, K., Onda, M., Morimoto, N., & Osakada, F. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.012 · Cited by 9
Tsai, E.-T., Peng, S., Wu, Y., Lin, T., Chen, C., Liu, Y., Tseng, Y.-H., Hsiao, Y., Tseng, H., Lai, W., et al. (2023) · Cells · doi:10.3390/cells12222617 · Cited by 9
“…demonstrated ideal potential to protect retinal ganglion cells from rotenone-induced cytotoxicity in vitro and in vivo, at least in the acute phase. cells from rotenone-induced cytotoxicity in vitro and in vivo, at least in the acute This highly immune-compatible iMSC product holds promise for…”
BackgroundSugita, S., Hono, A., Fujino, S., Futatsugi, Y., Yunomae, Y., Shimizu, N., & Takahashi, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212555 · Cited by 8
“In fact, for the clinical study of RPE transplantation, conventional tests (DNA staining and nested PCR) were performed two weeks before the operation, and Myco Finder PCR test was additionally conducted on the day of transplantation [2].”
BackgroundMethodSelf-citationSeah, I. Y. J., Liu, Z., Wong, D. S. L., Wong, W., Holder, G. E., Barathi, V. A., Gopal, L., Su, X., & Stanzel, B. V. (2021) · Journal of Visualized Experiments · doi:10.3791/62638 · Cited by 9
Tian, H., Chen, Z., Zhu, X., Ou, Q., Wang, Z., Wu, B., Xu, J., Jin, C., Gao, F., Wang, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105050 · Cited by 10
Metadata
- Authors
- Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., Amano, N., Sakaguchi, H., Hara, C., Maruyama, K., Daimon, T., Igeta, M., Oda, T., Shirono, U., Tozaki, M., Totani, K., Sugiyama, S., Nishida, K., Kurimoto, Y., & Takahashi, M.
- Affiliations
- RIKEN Center for Biosystems Dynamics Research (JP)
- Kobe City Medical Center General Hospital (JP)
- Toho University (JP)
- Kyoto University (JP)
- The University of Osaka (JP)
- Hyogo Medical University (JP)
- Tomey Corporation (Japan) (JP)
- Corresponding author
- Takahashi, Masayo
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-07-13
- Volume
- 9
- Issue
- 7
- Pages
- 2217
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7408794
- OpenAlex
- W3041366976
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 34 · 2023: 24 · 2022: 36 · 2021: 36 · 2020: 5
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AMED (JP18bm0204002, JP17bk0104002)
- KAKENHI (25293357, 18H02959, 16K21633)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- induced pluripotent stem cells, retinal pigment epithelium, cell transplantation, age-related macular degeneration, HLA matching, immune rejection, local steroid therapy, graft survival, transplant safety, epiretinal membrane, endophthalmitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.